A retrospective, cohort study describing patient characteristics, burden of disease, treatment patterns, and outcomes associated with mSS in EU-5 countries (France, Germany, Italy, Spain, and the UK) across multiple institutions
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Doxorubicin (Primary) ; Ifosfamide (Primary) ; Pazopanib (Primary) ; Trabectedin (Primary)
- Indications Synovial sarcoma
- Focus Therapeutic Use
- 02 Jun 2021 New trial record
- 21 May 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research